Basilea Pharmaceutica Ltd. Logo
 

Anti-Infectives 2013

 
 
 

Ceftobiprole

  • Assad F, Bhiki K, Eusebio D, Flores E, Paulino M, Ramirez A, Ramirez H, Valentin T, Zaman M, Sussman JL, Lovering AL, Westblade LF, Granberry A. Physical model of the staphylococcus aureus transpeptidase PBP2a in complex with an anti-methicillin-resistant staphylococcus aureus cephalosporin. FASEB J. 2013; 27.
  • Barnea Y, Navon-Venezia S, Kuzmenko B, Artzi N, Carmeli Y. Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model. Eur J Clin Microbiol Infect Dis. 2013; 1-5. [Article in Press]
  • Chen Y-H, Liu C-Y, Ko W-C, Liao C-H, Lu P-L, Huang C-H, Lu C-T, Chuang Y-C, Tsao S-M, Chen Y-S, Liu Y-C, Chen W-Y, Jang T-N, Lin H-C, Chen C-M, Shi Z-Y, Pan S-C, Yang J-L, Kung H-C, Liu C-E, Cheng Y-J, Liu J-W, Sun W, Wang L-S, Yu K-W, Chiang P-C, Lee M-H, Lee C-M, Hsu G-J, Hsueh P-R. Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010. Eur J Clin Microbiol Infect Dis. 2013; 1-7.
  • Garau J. New antibiotics. Int J Antimicrob Agents. 2013; 42: S28.
  • Howden BP, Beaume M, Harrison PF, Hernandez D, Schrenzel J, Seemann T, Francois P, Stinear TP. Analysis of the small RNA transcriptional response in multidrug-resistant staphylococcus aureus after antimicrobial exposure. Antimicrob Agents Chemother. 2013; 57(8): 3864-3874.
  • Kumar KM, Lavanya P, Anbarasu A, Ramaiah S. Molecular dynamics and molecular docking studies on E166A point mutant, R274N/R276N double mutant, and E166A/R274N/R276N triple mutant forms of class A β-lactamases. J Biomol Struct Dyn. 2013. [Article in Press]
  • Lagacé-Wiens PRS, Rubinstein E. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia. Expert Opin Drug Metab Toxicol. 2013; 9(6): 789-799.
  • Lee D-G, Murakami Y, Andes DR, Craig WA. Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with staphylococcus aureus and streptococcus pneumoniae at inocula of 10E5 and 10E7 CFU injected into opposite thighs of neutropenic mice. Antimicrob Agents Chemother. 2013; 57(3): 1434-1441.
  • Muhlebach MS. MRSA-update on epidemiology and treatment in CF. Pediatr Pulmonol. 2013; 48: 117-119.
  • Muller AE, Schmitt-Hoffmann AH, Punt N, Mouton JW. Monte carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: A validation study. Antimicrob Agents Chemother. 2013; 57(5): 2047-2053.
  • Scaglione F. In vitro-in vivo models for assessing antimicrobial combinations. Int J Antimicrob Agents. 2013; 42: S1.
  • Senneville E, Nguyen S. Current pharmacotherapy options for osteomyelitis: Convergences, divergences and lessons to be drawn. Expert Opin Pharmacother. 2013; 14(6): 723-734.
  • Shibl AM. New antibiotics for treatment of MRSA infections. Int J Antimicrob Agents. 2013; 42: S12.
  • Van Der Scheer FW, Kuessner D, De Silva S, Posthumus J, Bergman G. Economic evaluation of ceftobiprole compared to a combination of linezolid with ceftazidime in the management of hospitalised pneunomia in Scotland. Value Health. 2013; 16(7): A358.


  • ICAAC, 2013, A-472 / %fT>MIC Predicts the Microbiological Eradication at End of Treatment with Ceftriaxon or Ceftobiprole in Patients with Community Acquired Pneumonia. Muller AE, Punt N, Mouton JW.
  • ICAAC, 2013, C2-558 / Genotypic Characterization of Methicillin-resistant Staphylococcus aureus Strains Recovered from Pneumonia Clinical Trials for Ceftobiprole. Mendes RE, Deshpande LM, Costello AJ, Flamm RK, Jones RN.
  • ICAAC, 2013, E-132 / Ceftobiprole (BPR) and Ampicillin (AMP) Increase Daptomycin (DAP) Susceptibility in DAP Susceptible and Resistant and Vancomycin Resistant Enterococci (VRE). Werth BJ, Barber KE, Tran K, Rybak MJ.
  • ICAAC, 2013, E-138 / Activity of Ceftobiprole (BPR) Combination Regimens Against Multiple Strains of Staphylococcus aureus with Differing Resistance Phenotypes. Barber KE, Werth BJ, Ireland CE, Stone NE, Rybak MJ.
  • ECCMID, 2013, P-1629 / Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus including strains with reduced susceptibility to daptomycin, linezolid, and vancomycin. Flamm RK, Mendes RE, Sader HS, Jones RN.
  • ECCMID, 2013, P-1628 / Activity of ceftobiprole tested against clinical isolates of staphylococci and streptococci from European surveillance (2008-2010). Flamm RK, Sader HS, Streit JM, Jones RN.
  • ECCMID, 2013, P-1627 / Activity of ceftobiprole tested against Gram-negative clinical isolates from European medical centres. Flamm RK, Sader HS, Streit JM, Jones RN.
  • ECCMID, 2013, P-904 / %fT>MIC (minimum inhibitory concentration) predicts probability of clinical outcome in the treatment of nosocomial pneumonia by ceftobiprole. Muller AE, Punt N, Mouton JW.
  • ECCMID, 2013, P-1626 / Activity of ceftobiprole tested against pathogens associated with community-acquired bacterial pneumonia in Europe. Flamm RK, Sader HS, Jones RN.
  • ECCMID, 2013, P-1625 / Activity of ceftobiprole tested against pathogens associated with hospital-acquired bacterial pneumonia in Europe. Flamm RK, Sader HS, Streit JM, Jones RN.
 

Isavuconazole

  • Chowdhary A, Agarwal K, Kathuria S, Singh PK, Roy P, Gaur SN, De Hoog GS, Meis JF. Clinical significance of filamentous basidiomycetes illustrated by isolates of the novel opportunist ceriporia lacerata from the human respiratory tract. J Clin Microbiol. 2013; 51(2): 585-590.
  • Chowdhary A, Kathuria S, Singh PK, Agarwal K, Gaur SN, Roy P, Randhawa HS, Meis JF. Molecular characterization and in vitro antifungal susceptibility profile of schizophyllum commune, an emerging basidiomycete in bronchopulmonary mycoses. Antimicrob Agents Chemother. 2013; 57(6): 2845-2848.
  • Chowdhary A, Prakash A, Randhawa HS, Kathuria S, Hagen F, Klaassen CH, Meis JF. First environmental isolation of Cryptococcus gattii, genotype AFLP5, from India and a global review. Mycoses. 2013; 56(3): 222-228.
  • Datta K, Rhee P, Byrnes III E, Garcia-Effron G, Perlin DS, Staab JF, Marr KA. Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility. J Clin Microbiol. 2013; 51(9): 3090-3093.
  • Deng S, De Hoog GS, Badali H, Yang L, Najafzadeh MJ, Pan B, Curfs-Breuker I, Meis JF, Liao W. In vitro antifungal susceptibility of Cladophialophora carrionii, an agent of human chromoblastomycosis. Antimicrob Agents Chemother. 2013; 57(4): 1974-1977.
  • Desai A, Zadeikis N, Breese N, Yamazaki T, Kowalski D, Townsend R. Isavuconazole does not significantly affect the pharmacokinetics of p-glycoprotein substrate digoxin in healthy subjects. Clin Pharmacol Ther. 2013; 93: S40.
  • Desai A, Zadeikis N, Howieson C, Yamazaki T, Kowalski D, Townsend R. Isavuconazole does not affect prednisolone pharmacokinetics in healthy subjects following coadministration of multiple dose isavuconazole. Clin Pharmacol Ther. 2013; 93: S39.
  • Desai A, Zadeikis N, Pearlman H, Yamazaki T, Kowalski D, Townsend R. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP3A4 substrate tacrolimus in healthy subjects. Clin Pharmacol Ther. 2013; 93: S39-S40.
  • Ervens J, Ghannoum M, Graf B, Schwartz S. Successful isavuconazole salvage therapy in a patient with invasive mucormycosis. 2013; 1-4. [Article in Press]
  • Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Lass-Flörl C, Martin-Mazuelos E, Meis J, Peláez T, Pfaller MA, Turnidge J. Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for Aspergillus spp. for the CLSI M38-A2 Broth Microdilution Method. Antimicrob Agents Chemother. 2013; 57(8): 3823-3828.
  • Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013; 6: 163-174.
  • Gregson L, Goodwin J, Johnson A, McEntee L, Moore CB, Richardson M, Hope WW, Howard SJ. In vitro susceptibility of Aspergillus fumigatus to isavuconazole: Correlation with itraconazole, voriconazole, and posaconazole. Antimicrob Agents Chemother. 2013; 57(11): 5778-5780.
  • Hazirolan G, Canton E, Sahin S, Arikan-Akdagli S. Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii. Antimicrob Agents Chemother. 2013; 57(10): 4841-4847.
  • Howard SJ, Lass-Flörl C, Cuenca-Estrella M, Gomez-Lopez A, Arendrup MC. Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Antimicrob Agents Chemother. 2013; 57(11): 5426-5431.
  • Lepak AJ, Marchillo K, VanHecker J, Andes DR. Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother. 2013; 57(12): 6284-6289.
  • Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR. Isavuconazole pharmacodynamic target determination for Candida species in an in Vivo murine disseminated candidiasis model. Antimicrob Agents Chemother. 2013; 57(11): 5642-5648.
  • Lockhart SR, Pham CD, Gade L, Iqbal N, Scheel CM, Cleveland AA, Whitney AM, Noble-Wang J, Chiller TM, Park BJ, Litvintseva AP, Brandt ME. Preliminary laboratory report of fungal infections associated with contaminated methylprednisolone injections. J Clin Microbiol. 2013; 51(8): 2654-2661.
  • Najafzadeh MJ, Keisari MS, Vicente VA, Feng P, Shamsian SAA, Rezaei-Matehkolaei A, De Hoog GS, Curfs-Breuker I, Meisj JF. In vitro activities of eight antifungal drugs against 106 waterborne and cutaneous Exophiala species. Antimicrob Agents Chemother. 2013; 57(12): 6395-6398.
  • Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol. 2013; 51(8): 2608-2616.
  • Prakash A, Wankhede S, Singh PK, Agarwal K, Kathuria S, Sengupta S, Barman P, Meis JF, Chowdhary A. First neonatal case of fungaemia due to Pseudozyma aphidis and a global literature review. Mycoses. 2013. [Article in Press]
  • Sharma C, Wankhede S, Muralidhar S, Prakash A, Singh PK, Kathuria S, Kumar DA, Khan N, Randhawa HS, Meis JF, Chowdhary A. Candida nivariensis as an etiologic agent of vulvovaginal candidiasis in a tertiary care hospital of New Delhi, India. Diagn Microbiol Infect Dis. 2013; 76(1): 46-50.
  • Taj-Aldeen SJ, Kolecka A, Boesten R, Alolaqi A, Almaslamani M, Chandra P, Meis JF, Boekhout T. Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern. 2013; 1-12.  [Article in Press]
  • Townsend R, Desai A, Howieson C, Kowalski D, Pearlman H, Yamazaki T, Mujais S. Clinical considerations for coadministration of the novel antifungal isavuconazole with immunosuppressive agents. Transplant Int. 2013; 26: 227.
  • Yamazaki T, Zadeikis N, Pearlman H, Desai A, Kowalski D, Townsend R. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP3A4 substrate cyclosporine in healthy subjects. Clin Pharmacol Ther. 2013; 93: S114.
  • Yamazaki T, Zadeikis N, Pearlman H, Desai A, Kowalski D, Townsend R. Effect of multiple doses of isavuconazole on the pharmacokinetics of sirolimus in healthy subjects. Clin Pharmacol Ther. 2013; 93: S114.

  • ICAAC, 2013, A-291 / Pharmacodynamics (PD) of Isavuconazole (Isav) in a Murine Invasive Pulmonary Aspergillosis (IPA) Model Against Wildtype (WT) and Cyp51 Mutants. Lepak A, Marchillo K, Van Hecker J, Andes DR.
  • ICAAC, 2013, A-448 / No Effect on Pharmacokinetic and Pharmacodynamic Parameters of Warfarin after Coadministration with Isavuconazole. Yamazaki T, Desai A, Pearlman H, Kowalski D, Lademacher C, Townsend R.
  • ICAAC, 2013, A-449 / Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of CYP3A4 Substrate Atorvastatin in Healthy Subjects. Yamazaki T, Pearlman H, Kowalski D, Lademacher C, Desai A, Townsend R.
  • ICAAC, 2013, A-450 / Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of CYP2B6 Substrate Bupropion in Healthy Subjects. Desai A, Pearlman H, Yamazaki T, Lademacher C, Kowalski D, Townsend R.
  • ICAAC, 2013, A-451 / Impact of Candida species on the Isavuconazole (ISA) Pharmacodynamic (PD) Target in an in vivo Neutropenic Murine Model of Invasive Candidiasis (IC). Lepak A, Marchillo K, Van Hecker J, Diekema D, Andes DR.
  • ICAAC, 2013, M-759 / Pharmacokinetics and Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. Petraitiene R, Petraitis V, Moradi PW, Strauss GE, Huertas BT, Katragkou A, Petraityte E, Kovanda LL, Smart J, Hope WW, Walsh TJ.
  • ICAAC, 2013, M-787 / Isavuconazole Protects Immunosuppressed Mice from Rhizopus oryzae Infection. Luo G, Gebremariam T, Lee H, Edwards JE, Ibrahim AS.
  • ICAAC, 2013, M-1350 / In Vitro Activity of Antifungal Drugs against a Global Collection of 28 Clinical and Environmental Exserohilum Species Isolates. Meis JF, Madrid H, Breuker I, Hagen F, De Hoog GS, Chowdhary A.
  • ICAAC, 2013, M-1351 / Intra- and Interlaboratory Study of Antifungal Susceptibility Testing of Isavuconazole against Aspergillus Strains. Ghannoum MA, Chaturvedi V, Espinel-Ingroff A, Fothergill A, Jones R, Ostrosky-Zeichner L, Rennie R, Walsh T.
  • ICAAC, 2013, M-1362 / In Vitro Interaction Between Isavuconazole and Micafungin or Amphotericin B against Medically Important Moulds. Petraitis V, Meletiadis J, Moradi PW, Strauss GE, Kovanda LL, Petraitiene R, Walsh TJ.
  • ICAAC, 2013, M-1365 / Isavuconazole Susceptibility in Triazole Resistant Aspergillus fumigatus. Gregson L, Goodwin J, Johnson A, McEntee L, Moore CB, Richardson M, Hope WW, Howard SJ.
  • ICAAC, 2013, M-1372 / Activity of Isavuconazole, Amphotericin B, and Micafungin Alone and in Combination against Exserohilum rostratum. Moradi PW, Petraitis V, Petraitiene R, Strauss GE, Larone DH, Zhao Y, Forthergill AW, Ghannoum M, Simitsopoulou M, Roilides E, Kontoyiannis DP, Perlin DS, Walsh TJ.
  • ICAAC, 2013, M-1377 / In Vitro Activity of Isavuconazole compared with Itraconazole, Voriconazole, and Posaconazole in azole-resistant Aspergillus fumigatus. Seyedmousavi S, Rijs AJ, Melchers WJ, Mouton JW, Verweij PE.
  • ICAAC, 2013, M-1378 / Activity of Isavuconazole and Comparator Antifungals Tested Against Contemporary (2012) Fungal Clinical Isolates Collected Worldwide. Castanheira M, Messer SA, Rhomberg PR, Dietrich R, Jones RN, Pfaller MA.

  • ECCMID, 2013, P-983 / In-vitro activity of isavuconazole against Candida isolates from the EU and USA with reduced susceptibility to fluconazole: a pooled analysis from eight studies. Smart JI, Jones ME, Kovanda LL.
  • ECCMID, 2013, P-1001 / Microsatellite-typing of 458 Indian Cryptococcus neoformans var. grubii isolates and in-vitro susceptibility analysis. Chowdhary A, Hagen F, Prakash A, Kathuria S, Klaassen CHW, Meis JF.
  • ECCMID, 2013, P-1079 / Molecular characterisation of germ tube-positive Candida species with special reference to Candida Africana. Sharma C, Wankhede S, Prakash A, Kumar Singh P, Kathuria S, Chowdhary A.
  • ECCMID, 2013, O-167 / Molecular identification of clinically-significant non-sporulating basidiomycete moulds. Kumar Singh P, Kathuria S, Agarwal K, Roy P, Sybren De Hoog G, Meis JF, Chowdhary A.

 

BAL30072

  • ICAAC, 2013, F-1203 / In vitro Activity of BAL30072 against Biodefense Pathogens. Hershfield JR, Miller LL, Halasohoris SA, Page MG.
  • ECCMID, 2013, O-182 / In-vivo efficacy of the novel monosulfactam BAL30072 alone and in combination with meropenem against clinically important Gram-negative pathogens. Weiss W, Pulse M, Nguyen P, Pierce J, Valtierra D, Peterson K, Simecka J, Stubbings W.
  • ECCMID, 2013, P-908 / Efficacy of BAL30072 in murine thigh infection models of multi-resistant Gram-negative bacteria. Gould JK, Sattar A, Thommes P, Payne LJ, Stubbings W, Spickermann J, Daws G, Warn P.
  • ECCMID, 2013, P-1631 / BAL30072 combined with meropenem exhibits synergistic bactericidal activity against clinical New Delhi metallo beta-lactamase (NDM-1)-positive Enterobacteriaceae. Weeks J, Stubbings W, Walsh TR.
 
Info